Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 161 - 170 of 216

Selected Filters:
1 March 2022

High Prevalence of Curable STIs Among Young Women Initiating PrEP in Kenya and South Africa

This poster presents summary findings from 'The Prevention Options for Women Evaluation Research (POWER)' implementation project on the prevalence of curable STIs among young women initiating PrEP in Kenya and South Africa

Research, Testing

Document
1 March 2022

Oral PrEP Delivery Platforms: Are family planning clinics an option?

FP clinics may be an option for oral PrEP delivery for AGYW. This poster presents findings from an evaluation of PrEP uptake and provision at public and private family planning settings in Kisumu, Kenya.

Research, Service Delivery

Document
1 March 2022

PrEP Re-initiation After Interruption by Adolescent Girls and Young Women in Kenya and South Africa

Presentation made at AIS 2019 on evaluation of PrEP re-initiation after interruption amongst adolescent girls and young women in Kenya and South Africa

Research

Document
1 March 2022

“As long as my mother supports me, then I am okay”: Family influences on oral PrEP use among adolescent girls and young women in Kenya and South Africa

Efforts to build social support for PrEP have centered around peers and male partners, but family may also play an important role. This analysis highlights family influence on PrEP use among AGYW in the POWER Study conducted in South Africa and Kenya.

Research

Document
1 March 2022

Adolescent Girls’ PrEP Uptake from a Community-based Mobile Clinic: Early lessons from the POWER demonstration project

This presentation highlights lessons learnt from the POWER demonstration project on Adolescent girls’ PrEP uptake from a community-based mobile clinic

Research, Service Delivery

Document
1 March 2022

Early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African Adolescent Girls and Young Women (AGYW) from Kenya and South Africa

Understanding AGYW patterns of use is critical for scale up of PrEP programmes. This presentation highlights findings by the POWER project on early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African Adolescent Girls and Young Women (AGYW) from Kenya and South Africa

Research

Document
1 March 2022

High Prevalence and Incidence of Bacterial STIs in Young Women at High Risk of HIV Prior to PrEP scale-up in Kenya

PrEP roll-out programs provide a critical opportunity to address both HIV and STI epidemics simultaneously. This poster highlights the prevalence and incidence of bacterial STIs in young women at high risk of HIV prior to PrEP scale-up in Kenya

Research, Testing

Document
1 March 2022

Challenges with Oral Pre-Exposure Prophylaxis (PrEP) Disclosure Among Adolescent Girls and Young Women (AGYW) in Kenya and South Africa

PrEP use may be challenging to AGYW, given their need for social support and challenges with disclosure. This poster highlights challenges with Oral Pre-Exposure Prophylaxis (PrEP) Disclosure among Adolescent Girls and Young Women (AGYW) in Kenya and South Africa

Research

Document
1 March 2022

Prevention Options for Women Evaluation Research Key Informant Interviews Qualitative Report – July 2020

This is a report on Key Informant Interviews undertaken for the POWER Study, which aimed to characterize choice, uptake, and early adherence to PrEP, and sought to identify cost-effective and scalable delivery models to young women in Kenya and South Africa.

Research

Document
15 February 2022

MTN-034 REACH

Archived from the MTN website before it was taken down. Archived MTN-034 news page also available. Primary Objectives To compare the safety profiles of FTC/TDF oral tablet administered daily and dapivirine (25 mg) vaginal matrix ring inserted once every 4 weeks during the first 24 weeks of use of each study product in an adolescent…

Research